212.28 +0.22 (0.10%)
After hours: 7:46PM EST
Previous Close | 210.38 |
Open | 211.81 |
Bid | 212.45 x 1200 |
Ask | 214.00 x 800 |
Day's Range | 211.45 - 214.13 |
52 Week Range | 197.47 - 306.08 |
Volume | 2,346,983 |
Avg. Volume | 1,916,901 |
Market Cap | 55.127B |
Beta (5Y Monthly) | 0.64 |
PE Ratio (TTM) | 20.61 |
EPS (TTM) | 10.29 |
Earnings Date | Apr 27, 2021 - May 03, 2021 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 284.73 |
Back in 2016, Bank of America/Merrill Lynch issued a report that compared the performance of growth stocks to value stocks over a 90-year period (1926-2015). The results showed that value stocks were the superior choice (17% annual average return, versus 12.6% for growth stocks), albeit no investors are complaining with annual average returns of 12.6% or 17%. With lending rates at or near historic lows and the Federal Reserve remaining highly accommodative, growth stocks have run circles around value stocks for more than a decade.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Cowen Health Care Conference on Tuesday, March 2, 2021 at 9:50 a.m. ET.
Since the March 23 bear market low, the Dow Jones Industrial Average, S&P 500, and Nasdaq Composite are up a cool 70%, 76%, and 104%, respectively. Many of the same theses that bulls have extolled for years continue to drive Bitcoin's ascent. For example, fans still view its 21 million token limit as a hedge against the long-term devaluation of the U.S. dollar as the money supply increases.